相关实验视频
Updated: Jun 28, 2025

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
通过FBXO32介导的PTEN降解促进了肺腺癌的进展
Jie Wu1,2, Ting Wen3, Antonio Marzio4
1Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
过度表达FBXO32通过降解PTEN促进肺腺癌 (LUAD) 的进展,增强细胞循环,入侵和转移. 这项研究揭示了FBXO32作为LUAD的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- FBXO32 (F-box蛋白 32) 在癌症中具有双重作用,但其在肺腺癌 (LUAD) 中的功能尚未定义.
- 了解FBXO32在LUAD中的机制对于向治疗至关重要.
研究的目的:
- 阐明FBXO32在肺腺癌进展中的作用和分子机制.
- 调查FBXO32表达和患者预后之间的关系.
主要方法:
- 在LUAD组织中分析FBXO32表达和与患者存活率的相关性.
- 在体外功能测定 (细胞循环,入侵,转移) 和体内转移的小鼠模型.
- 蛋白质组分析,共免疫沉和西部涂抹以识别相互作用体和基质.
- 评价表皮质-介质酶过渡 (EMT) 和PTEN降解.
主要成果:
- FBXO32在LUAD中过度表达,并与预后不佳有关.
- 在体外和体内,FBXO32促进LUAD细胞周期失调,侵入和转移.
- FBXO32与PTEN相互作用并针对蛋白质体降解,激活PI3K/AKT/mTOR通路.
- 通过降解PTEN,FBXO32促进EMT和细胞循环进展.
结论:
- 过度表达FBXO32通过促进EMT和转移,推动LUAD的进展.
- 通过PTEN降解,FBXO32激活了PI3K/AKT/mTOR通路.
- FBXO32代表了肺腺癌的潜在治疗标.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...